297 related articles for article (PubMed ID: 34810235)
1. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
[TBL] [Abstract][Full Text] [Related]
2. Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
Wang L; Luo R; Onyshchenko K; Rao X; Wang M; Menz B; Gaedicke S; Grosu AL; Firat E; Niedermann G
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37640480
[TBL] [Abstract][Full Text] [Related]
3. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
4. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.
Uslu U; Sun L; Castelli S; Finck AV; Assenmacher CA; Young RM; Chen ZJ; June CH
Nat Commun; 2024 May; 15(1):3933. PubMed ID: 38730243
[TBL] [Abstract][Full Text] [Related]
5. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
Lai J; Mardiana S; House IG; Sek K; Henderson MA; Giuffrida L; Chen AXY; Todd KL; Petley EV; Chan JD; Carrington EM; Lew AM; Solomon BJ; Trapani JA; Kedzierska K; Evrard M; Vervoort SJ; Waithman J; Darcy PK; Beavis PA
Nat Immunol; 2020 Aug; 21(8):914-926. PubMed ID: 32424363
[TBL] [Abstract][Full Text] [Related]
6. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
Alvarez M; Molina C; De Andrea CE; Fernandez-Sendin M; Villalba M; Gonzalez-Gomariz J; Ochoa MC; Teijeira A; Glez-Vaz J; Aranda F; Sanmamed MF; Rodriguez-Ruiz ME; Fan X; Shen WH; Berraondo P; Quintero M; Melero I
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824158
[TBL] [Abstract][Full Text] [Related]
8. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
9. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
Barber A; Sentman CL
J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome them.
Zou SS; Qiao Y; Zhu S; Gao B; Yang N; Liu YJ; Chen J
Pharmacol Res; 2021 Apr; 166():105514. PubMed ID: 33631336
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
12. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
13. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
[TBL] [Abstract][Full Text] [Related]
14. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
15. STING licensing of type I dendritic cells potentiates antitumor immunity.
Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J
Sci Immunol; 2024 Feb; 9(92):eadj3945. PubMed ID: 38363830
[TBL] [Abstract][Full Text] [Related]
16. STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Perera SA; Kopinja JE; Ma Y; Muise ES; Laskey J; Chakravarthy K; Chen Y; Cui L; Presland J; Sathe M; Javaid S; Minnihan EC; Ferguson HM; Piesvaux J; Pan BS; Zhao S; Sharma SK; Woo HC; Pucci V; Knemeyer I; Cemerski S; Cumming J; Trotter BW; Tse A; Khilnani A; Ranganath S; Long BJ; Bennett DJ; Addona GH
Mol Cancer Ther; 2022 Feb; 21(2):282-293. PubMed ID: 34815361
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
18. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
19. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
